



Annual reports in medicinal chemistry [

Macor, John E.

Elsevier / Academic Press,
2011

Electronic books

Monografía

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies

<https://rebiunoda.pro.baratznet.cloud:38443/OpacDiscovery/public/catalog/detail/b2FpOmNlbGVicmF0aW9uOmVzLmJhcmF0ei5yZW4vMTk2NzI1MDc>

Título: Annual reports in medicinal chemistry electronic resource]. Volume 46 editor-in-chief: John E. Macor

Editorial: Amsterdam Boston Elsevier / Academic Press 2011

Descripción física: 1 online resource (600 p.)

Mención de serie: Annual reports in medicinal chemistry v. 46

Nota general: Description based upon print version of record

Bibliografía: Includes bibliographical references and index

Contenido: Front Matter; Annual Reports in Medicinal Chemistry; Copyright; Contents; Contributors; Preface; Part I:: Central Nervous System Diseases; Chapter 1: Progress in the Medicinal Chemistry of Group III Metabotropic Glutamate Receptors; 1. Introduction; 2. Group III Orthosteric Ligands; 2.1. Group III agonists; 2.2. Group III antagonists; 3. mGlu4 Receptor Allosteric Ligands; 3.1. mGlu4 receptor positive allosteric modulators; 3.2. mGlu4 receptor negative allosteric modulators; 4. mGlu6 Receptor Ligands; 5. mGlu7 Receptor Ligands; 6. mGlu8 Receptor Ligands; 7. Conclusions; References Chapter 2: Recent Advances Toward Pain Therapeutics1. Introduction; 2. Sodium Channel Blockers; 2.1. Nav subtypes as pain targets; 2.2. Pharmacological versus functional selectivity via state-dependent inhibition; 2.3. Subtype-selective inhibitors; 3. NGF/TrkA Pathway Interference; 3.1. NGF sequestration; 3.2. Inhibition of NGF/TrkA interaction; 3.3. TrkA kinase inhibitors; 4. FAAH Inhibitors; 4.1. Covalent FAAH inhibitors; 4.2. Noncovalent FAAH inhibitors; 5. Conclusions; References; Chapter 3: Central Modulation of Circadian Rhythm via CK1 Inhibition for Psychiatric Indications 1. Introduction2. Description of Circadian Clock; 3. CK1 Inhibitors; 3.1. Structure and function of CK1 enzymes; 3.2. Mechanism of action of CK1 inhibitors; 3.3. CK1 inhibitor chemical scaffolds; 4. Preclinical Animal Models; 5. Conclusions; References; Chapter 4: Recent Progress in the Discovery of Kv7 Modulators; 1. Introduction; 1.1. Function; 1.2. Structural biology; 2. Kv7.1 Channels; 3. Kv7.2-Kv7.5 Channels; 3.1. Function; 3.2. Binding sites; 3.3. Compounds in clinical development: Flupirtine, retigabine, and ICA105665; 3.4. Compounds in drug discovery

3.4.1. Efforts using retigabine/flupirtine as template3.4.2. Other Kv7 activators; 4. Conclusion; References; Part II:: Cardiovascular and Metabolic Diseases; Chapter 5: Bile Acid Receptor Modulators in Metabolic Diseases; 1. Introduction; 2. FXR Agonists; 3. TGR5 Agonists; 3.1. Non-BA agonists; 3.2. BA derivatives; 4. FXR/TGR5 Dual Agonists; 5. Clinical Studies and Outlook; References; Chapter 6: Recent Advances in Mineralocorticoid Receptor Antagonists; 1. Introduction; 2. Aldosterone and MR Biology; 3. RAAS Pathway, MR Antagonists versus ACE, ARB Therapy 3.1. Steroid-based MR antagonists in the clinic-Clinical results4. Structural Features of the Ligand Binding Domain of MR; 5. Current Medicinal Chemistry Efforts; 5.1. Dihydropyridines; 5.2. Pyrazoline derivatives; 5.3. Indole sulfonamides and related structures; 5.4. Benzimidazole derivatives; 5.5. Other MR antagonist structures; 6. Conclusions; References; Chapter 7: SGLT2 Inhibitors for Type 2 Diabetes; 1. Introduction; 2. SGLT2 Physiology; 2.1. Renal glucose reuptake by SGLT2 and SGLT1; 2.2. Glucosuria and regulation of plasma glucose; 3. Clinical Trials; 4. SGLT2 Inhibitors 4.1. Glucoside-based inhibitors

Lengua: English

ISBN: 1-283-29900-3 9786613299000 0-12-386024-5

Materia: Pharmaceutical chemistry Clinical chemistry

Autores: Macor, John Eugene

Entidades: American Chemical Society. Division of Medicinal Chemistry

Enlace a serie principal: Annual reports in medicinal chemistry (CKB)954926957872 (DLC)2005215188 (OCoLC)60625597 1557-8437

Enlace a formato físico adicional: 0-12-386009-1

Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- informa@baratz.es